Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Cash from Operations (2020 - 2025)

Historic Cash from Operations for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to -$13.0 million.

  • Pulse Biosciences' Cash from Operations fell 4449.25% to -$13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.5 million, marking a year-over-year decrease of 4275.92%. This contributed to the annual value of -$36.3 million for FY2024, which is 999.36% down from last year.
  • Latest data reveals that Pulse Biosciences reported Cash from Operations of -$13.0 million as of Q3 2025, which was down 4449.25% from -$12.8 million recorded in Q2 2025.
  • Over the past 5 years, Pulse Biosciences' Cash from Operations peaked at -$6.6 million during Q1 2023, and registered a low of -$16.4 million during Q2 2021.
  • In the last 5 years, Pulse Biosciences' Cash from Operations had a median value of -$10.6 million in 2022 and averaged -$11.0 million.
  • In the last 5 years, Pulse Biosciences' Cash from Operations tumbled by 10614.69% in 2021 and then surged by 5786.84% in 2023.
  • Pulse Biosciences' Cash from Operations (Quarter) stood at -$12.7 million in 2021, then soared by 37.25% to -$8.0 million in 2022, then increased by 14.85% to -$6.8 million in 2023, then tumbled by 34.83% to -$9.1 million in 2024, then plummeted by 42.6% to -$13.0 million in 2025.
  • Its Cash from Operations was -$13.0 million in Q3 2025, compared to -$12.8 million in Q2 2025 and -$13.5 million in Q1 2025.